Primary bioavailability parameters of loratadine in CYP2D6 extensive metabolizers

被引：0
|
作者：
Kunicki, PK
Gutkowski, P
机构：
[1] Natl Inst Cardiol, Dept Clin Biochem, Clin Pharmacol Unit, Warsaw, Poland
[2] TRIAL Clin Res Ctr, Warsaw, Poland
来源：
THERAPEUTIC DRUG MONITORING | 2003年 / 25卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
156
引用
收藏
页码：525 / 525
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers
    Pedersen, RS
    Damkier, P
    Brosen, K
    DRUG METABOLISM REVIEWS, 2005, 37 : 63 - 64
  • [2] Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers
    Pedersen, Rasmus Steen
    Damkier, Per
    Brosen, Kim
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (07) : 513 - 521
  • [3] Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers
    Rasmus Steen Pedersen
    Per Damkier
    Kim Brøsen
    European Journal of Clinical Pharmacology, 2006, 62 : 513 - 521
  • [4] CHLORPHENIRAMINE PLASMA ANTAGONIST ACTIVITY IN POOR AND EXTENSIVE METABOLIZERS OF CYP2D6
    YASUDA, SU
    BARBEY, JT
    HEWETT, J
    WOOSLEY, RL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 170 - 170
  • [5] Pharmacokinetic disposition of nebivolol in extensive and poor CYP2D6 metabolizers.
    Shaw, AA
    Ziemniak, J
    Liu, S
    Chervenick, SW
    Rackley, RJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P77 - P77
  • [6] Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers
    Li, Susie Xiujiang
    Pequignot, Edward
    Panebianco, Deborah
    Lupinacci, Paul
    Majumdar, Anup
    Rosen, Laura
    Ahmed, Tuli
    Royalty, Lane E.
    Rushmore, Thomas H.
    Murphy, M. Gail
    Petty, Kevin J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (07): : 792 - 801
  • [7] Modelling the pharmacokinetics of tramadol: On the difference between CYP2D6 extensive and poor metabolizers
    Di Patti, F.
    Fanelli, D.
    Pedersen, R. S.
    Giuliani, C.
    Torricelli, F.
    JOURNAL OF THEORETICAL BIOLOGY, 2008, 254 (03) : 568 - 574
  • [8] Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers
    DeVane, CL
    Markowitz, JS
    Carson, SW
    Boulton, DW
    Gill, HS
    Nahas, Z
    Risch, SC
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (03) : 347 - 349
  • [9] Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6
    Dilger, K
    Greiner, B
    Fromm, MF
    Hofmann, U
    Kroemer, HK
    Eichelbaum, M
    PHARMACOGENETICS, 1999, 9 (05): : 551 - 559
  • [10] POOR METABOLIZERS OF NICOTINE AND CYP2D6 POLYMORPHISM
    CHOLERTON, S
    ARPANAHI, A
    MCCRACKEN, N
    BOUSTEAD, C
    TABER, H
    JOHNSTONE, E
    LEATHART, J
    DALY, AK
    IDLE, JR
    LANCET, 1994, 343 (8888): : 62 - 63
12345